The global Biomarkers market reached a value of about USD 47.7 billion in 2021. The industry is projected to grow at a CAGR of around 15% in the forecast period of 2022-2027 to reach a value of about USD 110.4 billion by 2027.
The global Biomarkers industry report gives a comprehensive analysis of the industry, including key segments, trends, drivers, restraints, the competitive landscape, and other essential market aspects. The rising rate of chronic illnesses is driving the market growth. North America is the highest category spender by region, driving the demand for the Biomarkers industry.
A biomarker or a molecular marker can determine how effectively the body responds to a disease or condition therapy. A large subgroup of medical indicators – that is, objective signals of medical status viewed from outside the patient – can be assessed correctly. Biomarkers are frequently quantified and studied using blood, urine, or soft tissues to study normal biological processes, pathogenic processes, or pharmacologic reactions to a therapeutic intervention. The Biomarkers industry report consists of segments by type (Efficacy Biomarker, Validation Biomarker, and Safety Biomarker), the mechanism (Epigenetic Biomarkers, Genetic Biomarkers, Lipidomic Biomarkers, Proteomic Biomarkers, and Others), application (Diagnostic Biomarkers, Drug Discovery and Development, Secondary End Point Biomarkers, and Predictive Biomarkers), therapeutic area (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, and Renal Disorders) and region (North America, Europe, Asia Pacific, the Middle East, Africa, and South America).
North America holds the largest share in the industry due to the rising prevalence of chronic illnesses in the United States. In addition, the government is concentrating on biomarker research and development. In addition, rising consumer awareness, aggressive government efforts, technology advancements, and improvements in healthcare infrastructure are furthering the industry. The many growth strategies adopted by key players with established pharmaceutical companies in the area, and a higher adoption rate of biomarkers for diagnostics of disease, particularly in cancer diagnosis, contribute to the industry's expansion.
The market is being aided by the rising frequency of chronic illnesses paired with the developments in the methodologies used to generate biomarker-based diagnostics. Health conditions like cancer and cardiovascular disease and their rising frequency further the industry's expansion. Risk assessment, molecular diagnostics, illness diagnosis, DNA fingerprinting, and other molecular applications all employ biomarkers, thus resulting in increased demand. Biomarkers are utilised in imaging technology to give precise imaging of oncology tumours and other issues and reduce the risk of radiation exposure during C.T. and MRI scans; they can help with diagnosis, prognosis, and therapy selection. As a result, the market is witnessing an expansion of the following properties of the procedure. Other factors such as the growing geriatric population, personalised treatment, and the desire for cost-effective and efficient treatment doses are likely to impact the market positively.
However, factors such as the necessity for a significant initial investment, unfavourable regulatory and repayment policies, expensive tests, sample collection, storage costs, and a low benefit-cost ratio are likely to act as market restraints.
The global Biomarkers industry report by Procurement Resource gives an in-depth analysis of the best buying practices followed by major global Biomarkers regions, such as engagement models, contract terms, and buyer and supplier negotiation levers.
Almost any measurement reflects a biological system's interaction with a possible threat, whether chemical, physical, or biological. It might be a functional and physiological reaction, a pharmacological response at the cellular level, or a molecular interaction." Everything from pulse and blood pressure to fundamental chemistry to more complicated laboratory testing of blood and other tissues is an example of a biomarker.
The industry is witnessing growth due to the rising frequency of cancer which has boosted technology usage. Many firms are working to develop novel biomarker-based cancer detection tests or programmes that further stimulate the industry's growth. Governments and pharmaceutical corporations are also worried about the worldwide cost of cancer prevention and treatment, leading to investments in therapeutic innovation, resulting in the market's expansion. Diagnostic biomarker technology is shifting away from traditional pathophysiology/epidemiology approaches and toward biomarker studies like genomes and proteomics, furthering the industry's growth. Also, Neurological illnesses are becoming more curable because of recent advances in biomarkers, such as biomarker signatures. Noninvasive testing, speedier medication development, and early diagnosis have all resulted from this. Due to the following reasons, the market is likely to expand.
The regional markets for the industry can be divided into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific.
The biomarker market is competitive, but not too so. In drug development and clinical research, diagnostic biomarker tests are commonly employed. To improve their position in this market, these main competitors have used various organic and inorganic development tactics such as mergers and acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others. The improvement of technology and investment in R&D is critical to the market's success. Today, most pharmaceutical businesses participate in R&D, and governments also spend a significant amount of money on technological innovation.
1. Executive Summary
2. Biomarkers Market Snapshot
2.1. Biomarkers Market Outlook
2.2. Biomarkers Industry Analysis by Type
2.2.1. Safety Biomarker
2.2.2. Efficacy Biomarker
2.2.3. Validation Biomarker
2.3. Biomarkers Industry Analysis by Mechanism
2.3.1. Genetic Biomarkers
2.3.2. Epigenetic Biomarkers
2.3.3. Proteomic Biomarkers
2.3.4. Lipidomic Biomarkers
2.4. Biomarkers Industry Analysis by Application
2.4.1. Diagnostic Biomarkers
2.4.2. Drug Discovery and Development
2.4.3. Secondary End Point Biomarkers
2.4.4. Predictive Biomarkers
2.5. Biomarkers Industry Analysis by Therapeutic Area
2.5.2. Cardiovascular Disorders
2.5.3. Neurological Disorders
2.5.4. Immunological Disorders
2.5.5. Renal Disorders
2.6. Region Overview
2.6.1. North America
2.6.2. Asia Pacific
2.6.4. Latin America
2.6.5. Middle East and Africa
3. Impact of Recent Events
4. Biomarkers Value Chain Analysis
5. Biomarkers Production Process
6. Trade Analysis
7. Major Risk Factors in Sourcing
8. Biomarkers Cost Structure
9. Biomarkers Price Analysis
10. Key Demand Indicator Analysis
11. Key Price Indicator Analysis
12. Biomarkers Market Dynamics
12.1. Drivers & Constraints
12.2. Industry Events
12.3. Innovations & Trends
12.4. Swot Analysis
12.5. Porter’s Five Forces
12.5.1. Buyer Power
12.5.2. Supplier Power
12.5.3. Threat of New Entrants
12.5.4. Threat of Substitutes
12.5.5. Industry Rivalry
13. Industry Best Practices
13.1. Sourcing Strategy
13.2. Procurement Model
13.3. Contract Structure
13.4. Negotiation Levers
13.5. Pricing Model
13.6. Key Factors Influencing the Quotation
14. Key Supplier Analysis
14.1. Charles River Laboratories International, Inc
14.2. Laboratory Corporation of America Holdings
14.3. Eurofins Scientific Ltd.
14.5. WuXi AppTec Co., Ltd
The global Biomarkers market size was valued at USD 47.7 billion in 2021.
In the forecast period of 2022-2027, the market is projected to grow at a CAGR of 15%.
The significant demand for cancer treatment is one of the essential drivers of the Biomarkers market growth.
Charles River Laboratories International, Inc, Laboratory Corporation of America Holdings, Eurofins Scientific Ltd., PPD, Inc., and WuXi AppTec Co., Ltd are some of the major players in the market.
The North American region of the Biomarkers industry holds a significant share in the market.
The global Biomarkers market attained a value of USD 47.7 billion in 2021, driven by the rising frequency of chronic illnesses paired with the developments in the methodologies used to generate biomarker-based diagnostics. Other factors such as the growing geriatric population, personalised treatment, and the desire for cost-effective and efficient treatment doses are likely to impact the market positively. Aided by the rising frequency of cancer which has boosted technology usage, the market is expected to witness further growth in the forecast period of 2022-2027, growing at a CAGR of 15%. The market is projected to reach USD 110.4 billion by 2027. Some of the leading players in the industry are Charles River, LabCorp, Eurofins, PPD, and WuXi Apptec.
Procurement Resources' detailed research approach explores deep into the industry, encompassing the macro and micro aspects of the industry. Its team of experts uses a combination of cutting-edge analytical tools and their expertise, thus, delivering its customers with market insights that are accurate and actionable and help them remain ahead of their competition.
At Procurement Resource our analysts are selected after they are assessed thoroughly on having required qualities so that they can work effectively and productively and are able to execute projects based on the expectations shared by our clients. Our team is hence, technically exceptional, strategic, pragmatic, well experienced and competent.
We understand the cruciality of high-quality assessments that are important for our clients to take timely decisions and plan strategically. We have been continuously upgrading our tools and resources over the past years to become useful partners for our clientele. Our research methods are supported by most recent technology, our trusted and verified databases that are modified as per the needs help us serve our clients effectively every time and puts them ahead of their competitors.
Our team provides a detailed, high quality and deeply researched evaluations in competitive prices, that are unmatchable, and demonstrates our understanding of our client’s resource composition. These reports support our clientele make important procurement and supply chains choices that further helps them to place themselves ahead of their counterparts. We also offer attractive discounts or rebates on our forth coming reports.
Our vision is to enable our clients with superior quality market assessment and actionable evaluations to assist them with taking timely and right decisions. We are always ready to deliver our clients with maximum results by delivering them with customised suggestions to meet their exact needs within the specified timeline and help them understand the market dynamics in a better way.
Email Delivery Price: $ 999.00
The global nutmeg market reached a value of about 134 thousand tonnes in 2021. The industry is further expected to grow at a CAGR of about 4.5% in the forecast period of 2022-2027 to reach a value of around 167 thousand tonnes by 2027.Read More
Email Delivery Price: $ 999.00
The global HEOR market reached a value of about USD 1364.3 million in 2021. The industry is further expected to grow at a CAGR of about 12.81% in the forecast period of 2022-2027 to reach a value of around USD 2779.2 million by 2027.Read More
Email Delivery Price: $ 999.00
The global Artificial Intelligence Market reached a value of about USD 192 Billion in 2021. The industry is projected to grow at a CAGR of around 23% in the forecast period of 2022-2027 to reach a value of about USD 664.86 Billion by 2027.Read More